Rheologics buys blood vessel imaging company
This article was originally published in Clinica
Rheologics, which has developed a point-of-care whole blood viscosity measurement technology, has bought Cytometrics. The Delaware company develops non invasive point-of-care instrumentation for blood vessel imaging, which allows for better monitoring of perfusion changes in internal organs and in post-surgical disease states and requires no dye or surgery.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.